



800 NE Oregon St, Suite 370 Portland OR 97232

Medical Conditions or Other Indications for Administration of PCV13 and Administration and Revaccination with PPSV23

2-5 years old*† 6-64 years old ≥65 years old Single dose of PPSV23 **Risk Group** Age/Underlying PCV13^{*} Medical condition Revaccination Recommended Recommended at 5 years 0 Chronic heart disease§ **Immunocompetent** Chronic lung disease§ persons 0 **Diabetes Mellitus** 0 0 CSF leaks 0 Cochlear implants Alcoholism Chronic liver disease Cigarette smoking Asthma ≥ 65 years **Immunocompromised Persons:**

Sickle cell disease or other hemaglobinopathies •Congenital or acquired asplenia •Congenital or acquired immunodeficiencies[‡] •HIV infection •Chronic renal failure •Nephrotic syndrome•Leukemia •Lymphoma •Hodgkin disease •Generalized malignancy •latrogenic immunosuppression (including immunosuppressive drugs, long-term systemic corticosteroids and radiation therapy) •Solid organ transplant •Multiple myeloma •Those living in residential care centers

Pneumococcal Vaccine Scheduling Guide

The Oregon Health Authority determined that health care providers would benefit from a concise summary of the 2014 pneumococcal vaccine recommendations.

We created the table by first conducting a literature search of all ACIP recommendations related to both PCV13 and PPSV23, beginning in 2010. We combined the recommendations by age, by disease and recommendations for revaccination, into one table. Then we subdivided the table into two sections: one for immunocompetent persons with co-morbidities and the other for immunocompromised individuals. The reduction of the information evolved through several tables, each one more concise than previous versions. The final version resulted from collaboration between the author and Karen Landers, MD, MPH, Health Officer for Marion County, Oregon, with final approval by Paul Cieslak, MD, Medical Director for the Oregon Immunization Program and the Acute and Communicable Disease Prevention Section.

We are distributing the chart to Medical Assistant schools, local health departments, private practices, and pharmacies. The chart will also appear in the next versions of the Pneumococcal Vaccine Oregon Model Standing Order and Oregon Pharmacy Protocol. The chart can be downloaded at http://l.usa.gov/OregonStandingOrders.

Contact:

Jeanine R. Whitney, RN, MSN, NHE-C

Adult Immunization Public Health Nurse Center for Public Health Practice Immunization Program Oregon Health Authority

971-673-0281

jeanine.r.whitney@state.or.us

^{*2} doses of PCV13, at least 8 weeks apart if unvaccinated or any incomplete schedule of <3 doses.

†PCV13 approved for 2–5 years olds if treated with high-dose oral corticosteroid therapy. Not approved for asthma-only diagnosis in 6–18 year olds.

[§]PCV13: Particularly cyanotic congenital heart disease and cardiac failure in 2–5 year olds.

PPSV23: Chronic obstructive pulmonary disease, emphysema and asthma in persons ≥6 years of age.

†Includes B–(humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease).